EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Treprostinil (Primary) ; Treprostinil (Primary) ; Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms EXPEDITE
- Sponsors United Pharmaceuticals
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 29 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.